Hyaluronan-mediated motility receptor

Function

RHAMM was originally discovered as a soluble protein that altered migratory cell behavior and bound to hyaluronan. RHAMM is less well studied than the main hyaluronan (HA) receptor, CD44. In contrast to CD44 and other cell-surface receptors which contain the classical membrane spanning domain and signal sequence for secretion from the endoplasmic reticulum / Golgi complex, RHAMM does not contain a membrane spanning domain nor does the mRNA transcript contain a signal sequence. RHAMM is localized inside the cell and is unconventionally exported to the cell surface in response to certain defined stimuli such as wounding and cytokines including TGF-β. The precise unconventional export mechanism for transporting RHAMM to the extracellular space is still unclear but may involve transport channels or proteins, flippase activity, or exocytosis, similar to other non-conventionally exported cell surface proteins such as BFGF1,2 and epimorphin.

Intracellularly, RHAMM associates with microtubules and, working with BRCA1 and BARD1, plays a role in the regulation of mitosis, and in maintaining mitotic spindle integrity. RHAMM also binds directly with ERK1 and forms complexes with ERK1,2 and MEK1, suggesting a role as a scaffold protein that targets these MAP kinases to the nucleus.

Extracellularly, RHAMM associates with CD44, and upon binding to hyaluronan, activates intracellular signaling pathways, mainly the MAPK pathway via ERK1,2 activation Variants of RHAMM caused by alternative splicing have been observed, and alternative start codon usage has been proposed in mice and directly observed in humans.

Clinical significance

RHAMM is over expressed in breast cancer and its expression in triple negative and HER2 subtypes is associated with poor outcome. Alternatively spliced forms of RHAMM may be up regulated in some tumor types, promoting tumor progression. The presence of breast tumor cell subsets with high RHAMM expression is associated with reduced metastasis free survival and mediates migration, transformation, and metastatic spread of the triple negative human BCa cell line MDA-MB-231.

Elevated levels of RHAMM and hyaluronan are associated with the likelihood of undergoing biochemical failure in intermediate risk prostate cancer patients. RHAMM is also one of 3 biomarkers associated with aggressiveness in a multivariate analysis of human prostate tumors and elevated levels of RHAMM are associated with both androgen deprivation therapy and castration resistant disease. RHAMM has also been identified as one of 4 gene products identified in circulating tumor cells in patients with lung adenocarcinoma.

While RHAMM has been less studied than CD44 in the process of cancer metastasis, it is likely just as important in this process and can act in concert with, or independently of CD44 to promote cell motility. Increased RHAMM expression is correlated with metastases in colorectal cancer, among others. Mechanistically, RHAMM has been shown to promote cell motility through a number of different pathways. As with CD44, RHAMM can promote focal adhesion turnover by controlling focal adhesion kinase (FAK) phosphorylation and cooperating with the α4β1 and α5β1 integrins. RHAMM also activates a number of downstream kinases including enhancing the intensity and sustaining the duration of ERK1 / ERK2 activation through the map kinase (MAPK) pathway, pp60 (c-src), and the downstream targets of rho kinase (ROK). Finally, once a metastatic lesion has been established, RHAMM can cooperate with CD44 to promote angiogenesis by promoting migration of neighboring endothelial cells towards the tumor.

References

References

1. "Entrez Gene: HMMR hyaluronan-mediated motility receptor (RHAMM)".
2. (Mar 1999). "Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants". Blood.
3. (Oct 2000). "Alternative splicing of RHAMM gene in chinese gastric cancers and its in vitro regulation". Zhonghua Yi Xue Yi Chuan Xue Za Zhi = Zhonghua Yixue Yichuanxue Zazhi = Chinese Journal of Medical Genetics.
4. (Sep 2001). "Differential involvement of the hyaluronan (HA) receptors CD44 and receptor for HA-mediated motility in endothelial cell function and angiogenesis". The Journal of Biological Chemistry.
5. (June 2003). "RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability". Molecular Biology of the Cell.
6. (Jun 1992). "Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility". The Journal of Cell Biology.
7. (2004). "ONCOMINE: a cancer microarray database and integrated data-mining platform". Neoplasia.
8. (Mar 1991). "Hyaluronan and a cell-associated hyaluronan binding protein regulate the locomotion of ras-transformed cells". The Journal of Cell Biology.
9. (Nov 2006). "The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly". Cell.
10. (Jun 2007). "The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells". The Journal of Biological Chemistry.
11. (Nov 2007). "Network modeling links breast cancer susceptibility and centrosome dysfunction". Nature Genetics.
12. (Aug 2010). "RHAMM promotes interphase microtubule instability and mitotic spindle integrity through MEK1/ERK1/2 activity". The Journal of Biological Chemistry.
13. (Mar 2011). "How does a protein with dual mitotic spindle and extracellular matrix receptor functions affect tumor susceptibility and progression?". Communicative & Integrative Biology.
14. (May 2014). "Hyaluronan-mediated motility receptor (RHAMM) immunohistochemical expression and androgen deprivation in normal peritumoral, hyperplasic and neoplastic prostate tissue". BJU International.
15. (Jan 2014). "Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility". Proceedings of the National Academy of Sciences of the United States of America.
16. (Jun 2014). "Elevated hyaluronan and hyaluronan-mediated motility receptor are associated with biochemical failure in patients with intermediate-grade prostate tumors". Cancer.
17. (Apr 2014). "Evaluation of protein biomarkers of prostate cancer aggressiveness". BMC Cancer.
18. (Sep 2014). "Newly identified biomarkers for detecting circulating tumor cells in lung adenocarcinoma". The Tohoku Journal of Experimental Medicine.
19. (Oct 1982). "Purification of a hyaluronate-binding protein fraction that modifies cell social behavior". Biochemical and Biophysical Research Communications.
20. (Jul 1994). "Hyaluronan and the hyaluronan receptor RHAMM promote focal adhesion turnover and transient tyrosine kinase activity". The Journal of Cell Biology.
21. (Mar 1998). "The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression". Clinical Cancer Research.